Analysis of the clinical value for anti-Ro52 and anti-Ro60 antibodies in connective tissue disease

doi:10.3969/j.issn.1004-583X.2024.03.005

Abstract

Abstract:

Objective To investigate the clinical significance of anti-Ro52 and anti-Ro60 antibodies in connective tissue disease (CTD), and to analyze their potential in risk prediction of CTD-associated interstitial lung disease (CTD-ILD). Methods A total of 785 patients diagnosed as CTD and hospitalized in the Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University from October 2019 to January 2021 were enrolled in this study. Their clinical and laboratory data were collected. According to the testing result for anti-Ro52 and anti-Ro60 antibodies, patients were assigned into anti-Ro52⁺anti-Ro60^- group (n=94), anti-Ro52^-anti-Ro60⁺ group (n=80), anti-Ro52⁺anti-Ro60⁺ group (n=251) and anti-Ro52^-anti-Ro60^- group (n=360). According to the presence or absence of ILD, patients were assigned into CTD with ILD group (n=243) and CTD without ILD group (n=542). Clinical data were compared between groups. Multivariable logistic step-wise regression was performed to assess the potential of anti-Ro52 and anti-Ro60 antibodies in predicting the risk of CTD, especially CTD-ILD. Results Titers of anti-Ro52 and anti-Ro60 antibodies varied among enrolled patients. Significant differences were detected in the general information, clinicalsymptoms, cytokines, immunoglobulins, complements and autoantibodies between groups (P<0.05). Compared with females, the incidence of ILD increased by 56.7% in males. The risk of ILD increased by 3.8% for each additional year of age. Patients in the anti-Ro52⁺anti-Ro60^- group had a higher risk of ILD than those in other groups. Conclusion Positivity for anti-Ro52 antibody, male and old age are independent risk factors for ILD in CTD patients. Anti-Ro52 and anti-Ro60 antibodies have a complicated role in CTD, both of which should be used to replace the detection of traditional anti-SSA antibodies as independent variables to be examined.

Key words: connective tissue disease, lung disease, interstitial, anti-Ro52 antibodies, anti-Ro60 antibodies

CLC Number:

R593.2

Gong Sijing, Yang Yushu, Guo Huifang, Ding Meng, Wang Wei, Gao Lixia. Analysis of the clinical value for anti-Ro52 and anti-Ro60 antibodies in connective tissue disease[J]. Clinical Focus, 2024, 39(3): 227-233.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.03.005

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I3/227

Figures/Tables 7

References 28

[1]	Zhang Y, Li M, Zhang L, et al. Association between comorbidities and extraglandular manifestations in primary Sjögren's syndrome: A multicenter cross-sectional study[J]. Clin Rheumatol, 2020, 39(9):2677-2688. doi: 10.1007/s10067-020-04992-x pmid: 32146615
[2]	Fisseler-Eckhoff A, Märker-Hermann E. Interstitial lung disease associated with connective tissue disease[J]. Pathologe, 2021, 42(1):4-10. doi: 10.1007/s00292-020-00902-9 pmid: 33420569
[3]	Yoo H, Hino T, Han J, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management[J]. Eur J Radiol Open, 2021,8:100311.
[4]	Takada K, Takiguchi M, Konno A, et al. Spontaneous development of multiple glandular and extraglandular lesions in aged IQI/Jic mice: A model for primary Sjogren's syndrome[J]. Rheumatology (Oxford), 2004, 43(7):858-862.
[5]	Costa S, Schutz S, Cornec D, et al. B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: Development and validation of a pixel-based digital procedure[J]. Arthritis Res Ther, 2016,18:21.
[6]	Kurosawa M, Arakaki R, Yamada A, et al. NF-κB2 controls the migratory activity of memory T cells by regulating expression of CXCR4 in a mouse model of Sjögren's syndrome[J]. Arthritis Rheumatol, 2017, 69(11):2193-2202.
[7]	Hamberg V, Sohrabian A, Volkmann ER, et al. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study[J]. Arthritis Res Ther, 2023, 25(1):162. doi: 10.1186/s13075-023-03141-4 pmid: 37667402
[8]	Zanatta E, Cocconcelli E, Castelli G, et al. Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: Data from a large multicentric cohort[J]. RMD Open, 2023, 9(3) :e003121
[9]	Wu WJ, Mo HY, Liu H. Transbronchial lung cryobiopsy for connective tissue disease-related interstitial lung disease and interstitial pneumonia with autoimmune features: A single center retrospective case series[J]. Clin Rheumatol, 2021, 40(9):3765-3772.
[10]	Gualtierotti R, Ingegnoli F, Griffini S, et al. Detection of early endothelial damage in patients with Raynaud's phenomenon[J]. Microvasc Res, 2017,113:22-28.
[11]	Takeshita M, Suzuki K, Nakazawa M, et al. Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease[J]. J Autoimmun, 2021,121:102661.
[12]	Salvador-Corres I, Quirant-Sanchez B, Teniente-Serra A, et al. Detection of autoantibodies in bronchoalveolar lavage in patients with diffuse interstitial lung disease[J]. Arch Bronconeumol, 2021, 57(5):351-358. doi: 10.1016/j.arbres.2020.08.020 pmid: 33069461
[13]	Yang HT, Hong XP, Guo JW, et al. Clinical significance of different profiles of anti-Ro antibodies in connective tissue diseases[J]. J Immunol Res, 2023,2023:9195157.
[14]	Menor Almagro R, Jurado Roger A, Rodríguez Gutiérrez FJ, et al. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain[J]. Reumatol Clin, 2016, 12(5):256-262. doi: 10.1016/j.reuma.2015.10.010 pmid: 26725021
[15]	Song JS, Do JH, Lee SW. The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome[J]. Rheumatol Int, 2012, 32(2):491-495.
[16]	Lee A. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatol Int, 2017, 37(8):1323-1333.
[17]	Zampeli E, Mavrommati M, Moutsopoulos HM, et al. Anti-Ro52 and/or anti-Ro60 immune reactivity: Autoantibody and disease associations[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4):134-141. pmid: 32083547
[18]	Lee A, Beroukas D, Brown L, et al. Identification of a unique anti-Ro60 subset with restricted serological and molecular profiles[J]. Clin Exp Immunol, 2021, 203(1):13-21.
[19]	Robbins A, Hentzien M, Toquet S, et al. Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 antibody detection in autoimmune diseases[J]. Front Immunol, 2019,10:444.
[20]	Menéndez A, Gómez J, Caminal-Montero L, et al. Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus[J]. Sci. World J, 2013,2013:832789.
[21]	Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management[J]. Nat Rev Rheumatol, 2014, 10(12):728-739. doi: 10.1038/nrrheum.2014.149 pmid: 25266451
[22]	Carlicchi E, Caminati A, Fughelli P, et al. High-resolution CT in smoking-related interstitial lung diseases[J]. Int J Tuberc Lung Dis, 2021, 25(2):106-112. doi: 10.5588/ijtld.20.0622 pmid: 33656421
[23]	Fazeli MS, Khaychuk V, Wittstock K, et al. Rheumatoid arthritis-associated interstitial lung disease: Epidemiology, risk/prognostic factors, and treatment landscape[J]. Clin Exp Rheumatol, 2021, 39(5):1108-1118. doi: 10.55563/clinexprheumatol/h9tc57 pmid: 33635222
[24]	Shi X, Pu X, Cao D, et al. Clinical and prognostic features associated with anti-Ro52 autoantibodies in connective tissue diseases patients with interstitial lung disease[J]. Clin Exp Rheumatol, 2023.
[25]	Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020,172:106134.
[26]	Vojinovic T, Cavazzana I, Ceruti P, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis[J]. Clin Rev Allergy Immunol, 2021, 60(1):87-94.
[27]	Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome[J]. Respir Med, 2020,163:105895.
[28]	Wodkowski M, Hudson M, Proudman S, et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: Evidence of an association with interstitial lung disease and worse survival[J]. Clin Exp Rheumatol, 2015, 33(4Suppl 91): S131-135.

组别	例数	年龄 (岁)	男性 [例(%)]	临床症状[例(%)]
组别	例数	年龄 (岁)	男性 [例(%)]	发热	关节肿痛	肌痛/肌无力	皮疹	口干/眼干	光过敏	胸闷/气短	头晕/头痛
Ro52⁺Ro60^-组	94	53.10±15.68	11(11.7)	20(27.0)	32(43.2)	38(51.4)	24(32.9)	24(32.9)	2(2.7)	25(34.2)	3(4.1)
Ro52^-Ro60⁺组	80	45.75±17.06^*	7(8.8)	5(19.2)	13(50.0)	4(15.4)^*	4(15.4)	15(57.7)	1(3.8)	4(15.4)^*	0
Ro52⁺Ro60⁺组	251	42.39±14.77^*	18(7.2)	21(17.8)	47(40.2)	36(30.5)^*	27(23.5)	81(68.6)^*	1(0.9)	20(17.2)^*	8(7.0)
Ro52^-Ro60^-组	360	51.76±16.66^#△	77(21.4)^*#△	44(17.1)	195(75.6)^*#△	77(29.6)^*	60(23.2)	53(20.5)^#△	6(2.3)	52(20.1)	9(3.5)
F/χ²值		20.496	27.541	3.856	55.170	16.677	4.229	86.479	1.389	9.210	3.627
P值		<0.05	<0.05	0.277	<0.01	0.001	0.238	<0.01	0.708	0.027	0.305

组别	例数	年龄 (岁)	男性 [例(%)]	临床症状[例(%)]
组别	例数	年龄 (岁)	男性 [例(%)]	发热	关节肿痛	肌痛/肌无力	皮疹	口干/眼干	光过敏	胸闷/气短	头晕/头痛
Ro52⁺Ro60^-组	94	53.10±15.68	11(11.7)	20(27.0)	32(43.2)	38(51.4)	24(32.9)	24(32.9)	2(2.7)	25(34.2)	3(4.1)
Ro52^-Ro60⁺组	80	45.75±17.06^*	7(8.8)	5(19.2)	13(50.0)	4(15.4)^*	4(15.4)	15(57.7)	1(3.8)	4(15.4)^*	0
Ro52⁺Ro60⁺组	251	42.39±14.77^*	18(7.2)	21(17.8)	47(40.2)	36(30.5)^*	27(23.5)	81(68.6)^*	1(0.9)	20(17.2)^*	8(7.0)
Ro52^-Ro60^-组	360	51.76±16.66^#△	77(21.4)^*#△	44(17.1)	195(75.6)^*#△	77(29.6)^*	60(23.2)	53(20.5)^#△	6(2.3)	52(20.1)	9(3.5)
F/χ²值		20.496	27.541	3.856	55.170	16.677	4.229	86.479	1.389	9.210	3.627
P值		<0.05	<0.05	0.277	<0.01	0.001	0.238	<0.01	0.708	0.027	0.305

组别		例数	细胞因子(ng/L)
组别		例数	IL-1β		IL-2		IL-12p70		IL-17		IFN-α			IFN-γ		TNF-α
Ro52⁺Ro60^-组		94	8.39(2.76, 21.14)		2.24(1.39, 3.73)		1.14±0.63		2.30(1.37, 3.76)		3.17(1.46, 7.26)			6.83(2.40, 9.29)		3.68(1.88, 5.29)
Ro52^-Ro60⁺组		80	6.43(2.60, 16.00)		1.15(0.83, 1.52)^*		0.95±0.38		1.66(0.86, 1.74)^*		1.94(1.26, 3.79)^*			5.46(1.00, 9.53)		2.86(1.43, 4.07)
Ro52⁺Ro60⁺组		251	8.87(3.33, 20.97)		1.79(1.09, 2.71)^#		1.19±0.56^#		1.53(1.05, 2.64)^*#		2.85(1.64, 5.46)^#			7.02(3.21, 11.66)^#		2.81(1.52, 4.79)
Ro52^-Ro60^-组		360	8.74(2.66, 16.44)		1.44(0.99, 2.09)^*△		1.13±0.57^#		1.34(0.94, 1.91)^*△		1.76(1.24, 2.58)^*△			5.51(1.95, 10.17)^△		3.25(1.60, 5.62)
χ²/F/H值			4.077		45.406		3.093		40.924		49.390			8.370		5.365
P值			0.253		<0.01		0.027		<0.01		<0.01			0.033		0.147
组别	免疫指标(g/L)											自身抗体[例(%)]
组别	IgG			IgM		IgA		C3		C4		RF	抗CCP抗体		ANA		抗SSB抗体
Ro52⁺Ro60^-组	12.70(10.95, 15.20)			1.15(0.89, 1.45)		2.86(2.23, 3.60)		0.82±0.19		0.17(0.12, 0.24)		27(40.3)	10(27.8)		90(95.7)		2(2.1)
Ro52^-Ro60⁺组	13.60(10.55, 17.60)			1.00(0.70, 1.59)		2.93(2.19, 4.05)		0.63±0.27^*		0.12(0.08, 0.18)^*		18(29.5)	9(32.1)		80(100.0)		7(8.9)
Ro52⁺Ro60⁺组	18.40(13.63, 22.68)^*#			0.91(0.72, 1.17)^*		2.84(2.15, 3.78)		0.65±0.3^*		0.13(0.07, 0.19)^*		127(62.7)^*#	24(25.3)		249(99.6)^*		116(46.4)^*#
Ro52^-Ro60^-组	12.40(10.60, 15.80)^△			0.99(0.67, 1.38)^*		2.55(1.95, 3.33)		0.89±0.32^#△		0.20(0.13, 0.26)^#△		147(51.8)^#△	119(57.8)^*△		276(78.4)^*#△		0^*#△
χ²/F/H值	105.940			12.112		4.701		37.540		79.812		33.323	34.739		86.948		357.394
P值	<0.01			0.007		0.195		<0.01		<0.01		<0.01	<0.01		<0.01		<0.01

组别		例数	细胞因子(ng/L)
组别		例数	IL-1β		IL-2		IL-12p70		IL-17		IFN-α			IFN-γ		TNF-α
Ro52⁺Ro60^-组		94	8.39(2.76, 21.14)		2.24(1.39, 3.73)		1.14±0.63		2.30(1.37, 3.76)		3.17(1.46, 7.26)			6.83(2.40, 9.29)		3.68(1.88, 5.29)
Ro52^-Ro60⁺组		80	6.43(2.60, 16.00)		1.15(0.83, 1.52)^*		0.95±0.38		1.66(0.86, 1.74)^*		1.94(1.26, 3.79)^*			5.46(1.00, 9.53)		2.86(1.43, 4.07)
Ro52⁺Ro60⁺组		251	8.87(3.33, 20.97)		1.79(1.09, 2.71)^#		1.19±0.56^#		1.53(1.05, 2.64)^*#		2.85(1.64, 5.46)^#			7.02(3.21, 11.66)^#		2.81(1.52, 4.79)
Ro52^-Ro60^-组		360	8.74(2.66, 16.44)		1.44(0.99, 2.09)^*△		1.13±0.57^#		1.34(0.94, 1.91)^*△		1.76(1.24, 2.58)^*△			5.51(1.95, 10.17)^△		3.25(1.60, 5.62)
χ²/F/H值			4.077		45.406		3.093		40.924		49.390			8.370		5.365
P值			0.253		<0.01		0.027		<0.01		<0.01			0.033		0.147
组别	免疫指标(g/L)											自身抗体[例(%)]
组别	IgG			IgM		IgA		C3		C4		RF	抗CCP抗体		ANA		抗SSB抗体
Ro52⁺Ro60^-组	12.70(10.95, 15.20)			1.15(0.89, 1.45)		2.86(2.23, 3.60)		0.82±0.19		0.17(0.12, 0.24)		27(40.3)	10(27.8)		90(95.7)		2(2.1)
Ro52^-Ro60⁺组	13.60(10.55, 17.60)			1.00(0.70, 1.59)		2.93(2.19, 4.05)		0.63±0.27^*		0.12(0.08, 0.18)^*		18(29.5)	9(32.1)		80(100.0)		7(8.9)
Ro52⁺Ro60⁺组	18.40(13.63, 22.68)^*#			0.91(0.72, 1.17)^*		2.84(2.15, 3.78)		0.65±0.3^*		0.13(0.07, 0.19)^*		127(62.7)^*#	24(25.3)		249(99.6)^*		116(46.4)^*#
Ro52^-Ro60^-组	12.40(10.60, 15.80)^△			0.99(0.67, 1.38)^*		2.55(1.95, 3.33)		0.89±0.32^#△		0.20(0.13, 0.26)^#△		147(51.8)^#△	119(57.8)^*△		276(78.4)^*#△		0^*#△
χ²/F/H值	105.940			12.112		4.701		37.540		79.812		33.323	34.739		86.948		357.394
P值	<0.01			0.007		0.195		<0.01		<0.01		<0.01	<0.01		<0.01		<0.01

组别	例数	pSS是否合并ILD		PM/DM是否合并ILD		RA是否合并ILD		SLE是否合并ILD		SSc是否合并ILD
组别	例数	是	否	是	否	是	否	是	否	是	否
Ro52⁺Ro60^-组	94	9(9.6)	8(8.5)	28(29.8)	12(12.8)	5(5.3)	5(5.3)	6(6.4)	15(16.0)	4(4.2)	2(2.1)
Ro52^-Ro60⁺组	80	8(10.0)	6(7.5)	0	0	5(6.2)	3(3.8)	8(10.0)	48(60.0)	2(2.5)	0
Ro52⁺Ro60⁺组	251	28(11.2)	58(23.1)	9(3.5)	3(1.2)	3(1.2)	12(4.8)	12(4.8)	123(49.0)	1(0.4)	2(0.8)
Ro52^-Ro60^-组	360	10(2.8)	12(3.3)	30(8.3)	31(8.6)	46(12.8)	122(33.9)	21(5.8)	79(21.9)	8(2.3)	1(0.3)
χ²值		5.166		5.711		7.242		9.798		4.593
P值		0.160		0.058		0.065		0.020		0.204